Sustainability of Influenza Vaccine Production

By GPO, Thailand

Witit Artavatkun, M.D.
Managing Director
A state enterprise under the Ministry of Public Health

Founded in 1966 according to the GPO Act of 1966

Annual Revenue of year 2011: 340 mUSD

Total Pharmaceutical Products: 300+ items

Total staff: 2,896 (only 150 staff working on biological products)

Biological Products: JEV, TAT, Antivenom

Future Products: Flu, DTaP-HB
Sustainability of GPO Flu Project

**Policy Sustainability:**
- National security for pandemic preparedness
- Government controlling and balancing vaccine demand & supply

**Financial Sustainability**
- 100% Investment from Thai Government with NO analysis of return on investment

**Market Sustainability**
- Government (via NHSO) is the vaccine buyer, as part of Thailand’s Universal Coverage Scheme. This is the sustainable market.

**Technological Sustainability**
- WHO, IEM (LAIV), KAKETSUKEN (IIV), US & Japan Government
To have Sustainability on Vaccine Production

Maintain Gov. Policy
- Commit to support project on vaccine procurement

Establish Demand
- Establish vaccine user
- Create awareness on pandemic & its prevention

Maintain Supply
- Build capacity on vaccine R&D
- Support vaccine registration
- Strengthen collaboration & Networking
Thank you